Advertisment

Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:1700

Official publication of the Indian Society of Nephrology

Ahead of print articles
LETTER TO EDITOR
Ahead of print publication  

Rhodotorula mucilaginosa: Rare cause of fungal peritonitis


 Department of Nephrology, Indira Gandhi Medical College and Hospital, Shimla, Himachal Pradesh, India

Date of Submission22-Feb-2022
Date of Acceptance06-Apr-2022
Date of Web Publication16-Jul-2022

Correspondence Address:
Asheesh Kumar,
Department of Nephrology, Indira Gandhi Medical College and Hospital Shimla, Himachal Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijn.ijn_79_22



How to cite this URL:
Kumar A, Chauhan N. Rhodotorula mucilaginosa: Rare cause of fungal peritonitis. Indian J Nephrol [Epub ahead of print] [cited 2022 Dec 6]. Available from: https://www.indianjnephrol.org/preprintarticle.asp?id=351273

Fungal infections are an uncommon but serious cause of peritoneal dialysis (PD)-associated peritonitis.[1] The incidence worldwide is heterogeneous, with rates varying from 2% to 23.8%.[2] Despite its rarity, fungal peritonitis (FP) is important due to its associated higher rates of catheter loss, morbidity, and mortality. Candida species are the commonest pathogen isolated in FP, accounting for 70%–90% of the cases described.[3] Both early PD catheter removal and prompt antifungal treatment are considered the best strategies to improve patients' survival in FP.[4] Permanent transfer to hemodialysis remains frequent among survivors, although PD resumption has been described, especially in less-fragile patients.[5] We describe a case where Rhodotorula mucilaginosa was isolated from a patient's peritoneal dialysate. The organism has also been isolated from central venous catheters, suggesting that the hemodialysis population could also be at risk.[6]

A 58-year-old female with chronic kidney disease (CKD) stage 5 along with comorbidities of hypertension and hypothyroidism was started on PD. She underwent training for PD and performing the procedure by herself. She had three exchanges per day, two with 2.5% and one with 1.5% with glucose-based PD solution. Her urine output was 1800 ml/day. After 4 months of PD, she presented to us with cloudy PD fluid. She was, however, asymptomatic, having no pain abdomen or fever. In view of suspected peritonitis, her PD fluid was drawn for relevant investigations and she was started on intraperitoneal injections of vancomycin (1 g) every fourth day and meropenem (1 g) daily. PD fluid total leukocyte count was 650/mm3 along with 55% lymphocytes. No organism was seen on gram stain and KOH preparation. On culture of PD fluid, the colonies were grown after 7 days of incubation in Sabouraud medium and identified as R. mucilaginosa. Her other investigation reports revealed hemoglobin (Hb)- 9.8 g/dl, total leukocyte count (TLC)- 8100/mm3, platelet count- 108,000/μl, blood urea nitrogen- 91 mg/dl, serum creatinine- 4.9 mg/dl, serum potassium- 4.9 mEq/l, serum sodium- 143 mEq/l, serum calcium- 9.2 mg/dl, serum phosphorus- 4.4 mg/dl, aspartate aminotransferase- 12 IU/l, alanine aminotransferase- 16 IU/l, alkaline phosphatase- 107 IU/l, total serum protein- 5.8 g/dl, serum albumin- 3.6 g/dl, prothrombin time- 14.2 s, and international normalized ratio (INR)- 1.04.

On identification of fungus R. mucilaginosa in her PD dialysate, her PD catheter was removed and she was started on intravenous injection of amphotericin B deoxycholate (1 mg/kg/day) and was continued for 2 weeks. She was shifted to hemodialysis through right internal jugular tunneled cuff catheter (TCC) and subjected to right radiocephalic arteriovenous fistula (AVF) formation. Her AVF started working after 2 months and TCC was removed thereafter. On follow-up after 6 months, she is stable and doing well on hemodialysis.

Fungal infections are becoming an increasing health-care burden. Unfortunately, the number of causative pathogens, particularly affecting immunocompromised patients, is growing, without an expansion in treatment options.[7] R. mucilaginosa is a common environmental yeast that is isolated from air, ocean, soil, and plants.[8] In humans, it is a temporary commensal microorganism of the skin, nails, and gastrointestinal, urinary, and respiratory tracts.[9] Rhodotorula spp. is emerging as a causative agent in catheter-associated fungemia and peritonitis which is more relevant in context to our renal patients. It is also responsible for other infections such as meningitis, endocarditis, and prosthetic joint infections.[10],[11]

We describe the first case of R. mucilaginosa causing PD peritonitis from India. According to Franconieri, till now, there are 10 reported cases of R. mucilaginosa that has been isolated in peritoneal dialysate. Ninety percent of these patients had received antibiotics for peritonitis, but in our patient, there was no history of prior peritonitis and antibiotics. Also, there was no associated predisposing comorbidities like diabetes or use of immunosuppressive therapy in our patient. Simultaneous removal and reinsertion of PD catheter was tried in one of the patients among 10 patients, but it was not successful. Similar to other patients, our patient was also shifted to hemodialysis.[12]

As per previous reports, amphotericin B and flucytosine demonstrated good activity against this yeast. We started intravenous amphotericin B deoxycholate in our patient and she improved significantly. Caspofungin and azoles should not be used in the treatment of this fungus because of high minimum inhibitory concentration (MIC) for these drug agents. New azole molecule, isavuconazole, can be used as an alternative therapeutic agent in Rhodotorula infections, but well-designed studies are needed to evaluate this treatment.[13] We should suspect Rhodotorula infection in cases of nonresponse in FP despite the use of fluconazole.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Matuszkiewicz–Rowinska J. Update on fungal peritonitis and its treatment. Perit Dial Int 2009;29:161-5.  Back to cited text no. 1
    
2.
Auricchio S, Giovenzana ME, Pozzi M, Galassi A, Santorelli G, Dozio B, et al. Fungal peritonitis in peritoneal dialysis: A 34-year single centre evaluation. Clin Kidney J 2018;11:874-80.  Back to cited text no. 2
    
3.
Hu S, Tong R, Bo Y, Ming P, Yang H. Fungal peritonitis in peritoneal dialysis: 5-year review from a North China center. Infection 2019;47:35-43.  Back to cited text no. 3
    
4.
Wang AYM, Yu AWY, Li PKT, Lam PKW, Leung CB, Lai KN, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: Analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000;36:1183-92.  Back to cited text no. 4
    
5.
Nadeau-Fredette A-C, Bargman JM. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. Perit Dial Int 2015;35:78-84.  Back to cited text no. 5
    
6.
Duggal S, Jain H, Tyagi A, Sharma A, Chugh T. Rhodotorula fungemia: Two cases and a brief review. Med Mycol 2011;49:879-82.  Back to cited text no. 6
    
7.
Carnall VJ, Murdock S, Auckland C, Mulgrew CJ. Along came a spider: An unusual organism identified in a peritoneal dialysis patient, a case report and literature review. BMC Nephrol 2020;21:1-5.  Back to cited text no. 7
    
8.
Chaud LC, Lario LD, Bonugli-Santos RC, Sette LD, Junior AP, Felipe MdGdA. Improvement in extracellular protease production by the marine antarctic yeast Rhodotorula mucilaginosa L7. N Biotechnol 2016;33:807-14.  Back to cited text no. 8
    
9.
Capoor M, Aggarwal S, Raghvan C, Gupta D, Jain A, Chaudhary R. Clinical and microbiological characteristics of Rhodotorula mucilaginosa infections in a tertiary-care facility. Indian J Med Microbiol 2014;32:304-9.  Back to cited text no. 9
[PUBMED]  [Full text]  
10.
Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol 2008;25:135-40.  Back to cited text no. 10
    
11.
Ünal A, Koc A, Sipahioglu M, Kavuncuoglu F, Tokgoz B, Buldu H, et al. CAPD-related peritonitis caused by Rhodotorula mucilaginosa. Perit Dial Int 2009;29:581-2.  Back to cited text no. 11
    
12.
Franconieri F, Bonhomme J, Doriot A, Bonnamy C, Ficheux M, Lobbedez T, et al. Fungal peritonitis caused by Rhodotorula mucilaginosa in a capd patient treated with liposomal Amphotericin B: A case report and literature review. Perit Dial Int 2018;38:69-73.  Back to cited text no. 12
    
13.
Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother 2005;55:312-6.  Back to cited text no. 13
    




 

 
Top
 
 
  Search
 
  

 
  In this article
   References

 Article Access Statistics
    Viewed301    
    PDF Downloaded13    

Recommend this journal

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07